Cargando…
The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
Osteosarcoma (OS) is the most common primary malignancy of bone and affects patients in the first two decades of life. The greatest determinant of survival is the presence of pulmonary metastatic disease. The role of epigenetic regulation in OS, specifically the biology of metastases, is unknown. Ou...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346695/ https://www.ncbi.nlm.nih.gov/pubmed/25785263 http://dx.doi.org/10.1155/2015/290368 |
_version_ | 1782359730851676160 |
---|---|
author | Mu, Xiaodong Brynien, Daniel Weiss, Kurt R. |
author_facet | Mu, Xiaodong Brynien, Daniel Weiss, Kurt R. |
author_sort | Mu, Xiaodong |
collection | PubMed |
description | Osteosarcoma (OS) is the most common primary malignancy of bone and affects patients in the first two decades of life. The greatest determinant of survival is the presence of pulmonary metastatic disease. The role of epigenetic regulation in OS, specifically the biology of metastases, is unknown. Our previous study with the murine OS cell populations K7M2 and K12 demonstrated a significant correlation of metastatic potential with the DNA methylation level of tumor suppressor genes. In the current study, we investigated if the histone deacetylase (HDAC) inhibitor, vorinostat, could regulate the metastatic potential of highly metastatic OS cells. Our results revealed that vorinostat treatment of highly metastatic K7M2 OS cells was able to greatly reduce the proliferation and metastatic potential of the cells. Morphological features related to cell motility and invasion were changed by vorinostat treatment. In addition, the gene expressions of mTOR, ALDH1, and PGC-1 were downregulated by vorinostat treatment. These data suggest that vorinostat may be an effective modulator of OS cell metastatic potential and should be studied in preclinical models of metastatic OS. |
format | Online Article Text |
id | pubmed-4346695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-43466952015-03-17 The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells Mu, Xiaodong Brynien, Daniel Weiss, Kurt R. Biomed Res Int Research Article Osteosarcoma (OS) is the most common primary malignancy of bone and affects patients in the first two decades of life. The greatest determinant of survival is the presence of pulmonary metastatic disease. The role of epigenetic regulation in OS, specifically the biology of metastases, is unknown. Our previous study with the murine OS cell populations K7M2 and K12 demonstrated a significant correlation of metastatic potential with the DNA methylation level of tumor suppressor genes. In the current study, we investigated if the histone deacetylase (HDAC) inhibitor, vorinostat, could regulate the metastatic potential of highly metastatic OS cells. Our results revealed that vorinostat treatment of highly metastatic K7M2 OS cells was able to greatly reduce the proliferation and metastatic potential of the cells. Morphological features related to cell motility and invasion were changed by vorinostat treatment. In addition, the gene expressions of mTOR, ALDH1, and PGC-1 were downregulated by vorinostat treatment. These data suggest that vorinostat may be an effective modulator of OS cell metastatic potential and should be studied in preclinical models of metastatic OS. Hindawi Publishing Corporation 2015 2015-02-17 /pmc/articles/PMC4346695/ /pubmed/25785263 http://dx.doi.org/10.1155/2015/290368 Text en Copyright © 2015 Xiaodong Mu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mu, Xiaodong Brynien, Daniel Weiss, Kurt R. The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells |
title | The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells |
title_full | The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells |
title_fullStr | The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells |
title_full_unstemmed | The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells |
title_short | The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells |
title_sort | hdac inhibitor vorinostat diminishes the in vitro metastatic behavior of osteosarcoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346695/ https://www.ncbi.nlm.nih.gov/pubmed/25785263 http://dx.doi.org/10.1155/2015/290368 |
work_keys_str_mv | AT muxiaodong thehdacinhibitorvorinostatdiminishestheinvitrometastaticbehaviorofosteosarcomacells AT bryniendaniel thehdacinhibitorvorinostatdiminishestheinvitrometastaticbehaviorofosteosarcomacells AT weisskurtr thehdacinhibitorvorinostatdiminishestheinvitrometastaticbehaviorofosteosarcomacells AT muxiaodong hdacinhibitorvorinostatdiminishestheinvitrometastaticbehaviorofosteosarcomacells AT bryniendaniel hdacinhibitorvorinostatdiminishestheinvitrometastaticbehaviorofosteosarcomacells AT weisskurtr hdacinhibitorvorinostatdiminishestheinvitrometastaticbehaviorofosteosarcomacells |